false
English
Catalog
2023 World Conference on Lung Cancer (Posters)
EP12.01. Combination of Osimertinib plus Capmatini ...
EP12.01. Combination of Osimertinib plus Capmatinib in a Patient with EGFR-mutant, T790M positive and MET amplification: A Case Report - PDF(Slides)
Back to course
Pdf Summary
This case report describes the treatment of a patient with metastatic non-small cell lung cancer (NSCLC), who had an epidermal growth factor receptor (EGFR) mutation (T790M positive) and MET amplification. Osimertinib, a standard treatment for NSCLC with EGFR T790M mutation, was combined with capmatinib as a late-line treatment. The patient, a 70-year-old woman, initially presented with chronic cough and multiple bone pain. Further testing revealed EGFR exon 21 L858R mutation and negative results for other mutations. She received erlotinib as frontline treatment and achieved a partial response. However, 21 months later, disease progression was observed and osimertinib was administered as second-line treatment. The patient had stable disease until she developed progressive dyspnea. Pulmonary adenocarcinoma with TTF-1 positive was confirmed, along with EGFR exon21 L858R, exon20 T790M, TP53 mutations, and MET amplification. Osimertinib was then combined with capmatinib as third-line treatment. The patient initially had stable disease but decided to stop further treatment due to performance status decline and pursue best supportive care. The efficacy of the combination therapy was different from previous reports, indicating a marginal effect in this subgroup. This case highlights the potential benefit of combining osimertinib and capmatinib in patients with NSCLC who have both EGFR T790M mutation and MET amplification.
Asset Subtitle
Kijjakom Thanasombunsukh
Meta Tag
Speaker
Kijjakom Thanasombunsukh
Topic
Metastatic NSCLC: Targeted Therapy - EGFR/HER2
Keywords
metastatic non-small cell lung cancer
NSCLC
epidermal growth factor receptor
EGFR mutation
T790M positive
MET amplification
osimertinib
capmatinib
late-line treatment
pulmonary adenocarcinoma
×
Please select your language
1
English
5
普通话
11
Dutch